Articles | Volume 3, issue 1
Research article
20 May 2022
Research article |  | 20 May 2022

Imatinib disassembles the regulatory core of Abelson kinase by binding to its ATP site and not by binding to its myristoyl pocket

Stephan Grzesiek, Johannes Paladini, Judith Habazettl, and Rajesh Sonti

It was recently reported (Xie et al., 2022) that the Abelson tyrosine kinase (Abl) ATP-site inhibitor imatinib also binds to Abl's myristoyl binding pocket, which is the target of allosteric Abl inhibitors. This was based on a crystal structure of a truncated Abl kinase domain construct in complex with imatinib bound to the allosteric site as well as further isothermal titration calorimetry (ITC), NMR, and kinase activity data. Although imatinib's affinity for the allosteric site is significantly weaker (10 µM) than for the ATP site (10 nM), imatinib binding to the allosteric site may disassemble the regulatory core of Abl, thereby stimulating kinase activity, in particular for Abl mutants with reduced imatinib ATP-site affinity. It was argued that the previously observed imatinib-induced opening of the Abl regulatory core (Skora et al., 2013; Sonti et al., 2018) may be caused by the binding of imatinib to the allosteric site and not to the ATP site. We show here that this is not the case but that indeed imatinib binding to the ATP site induces the opening of the regulatory core at nanomolar concentrations. This agrees with findings that other type-II ATP-site inhibitors (nilotinib, ponatinib) disassemble the regulatory core despite demonstrated negligible binding to the allosteric site.

1 Introduction

Abelson tyrosine kinase (Abl) is crucial for many healthy cellular processes including proliferation, division, survival, DNA repair, and migration (Van Etten, 1999; Pendergast, 2002). However, the oncogenic Philadelphia chromosomal translocation leads to the expression of the highly active fusion protein Bcr-Abl and subsequently to chronic myeloid leukemia (CML) (Rowley, 1973; Deininger et al., 2000; Braun et al., 2020). The ATP-site inhibitors imatinib (Gleevec), nilotinib (Tasigna), and dasatinib (Sprycel) constitute the front-line therapy against CML (Hantschel et al., 2012; O'Hare et al., 2009; Shah et al., 2007). The recently FDA1-approved allosteric inhibitor asciminib (ABL001) (Wylie et al., 2017), which targets the myristoyl binding pocket (specifically targeting the ABL myristoyl pocket; STAMP), provides now additional therapeutic means, in particular to overcome emerging resistances against ATP-site inhibitors (Réa et al., 2021).

Figure 1Proposed mechanisms of imatinib-induced disassembly of Abl's regulatory core. (a) Crystal structure of Abl regulatory core (PDB ID: 2FO0) in complex with ATP-site inhibitor PD166326 (magenta sticks) and myristic acid (yellow spheres). Abl SH3 (blue) and SH2 (yellow) domains, KD N- and C-lobes (“KD-N”, “KD-C”, green), and linker regions (grey) are shown as cartoon. Residues Y245 (see text) and E518 (end of Abl248–518 construct used for crystal structure in P3) are shown as single blue spheres. (b) Model of Abl83–534imatinib complex as derived by rigid-body refinement with RDC and SAXS data in P1. The calculations revealed a large range of possible relative positions of SH3, SH2, and KD domains in agreement with the large-amplitude relative motions of the domains that were observed by 15N relaxation data. Only one of these conformations is shown in the panel. (c) Mechanical model explaining the allosteric coupling between A-loop and P-loop conformations, the flexibility of the αI helix, and the Abl core assembly state induced by ATP- and allosteric-site ligands as proposed in P2. Binding of the type-II inhibitor imatinib (magenta) to the ATP site induces a rotation of the kinase N-lobe towards the SH3 domain, which together with forces exerted by the flexible αI helix onto the SH2 domain leads to core disassembly. Binding of allosteric-site inhibitors such as GNF-5 or asciminib to the myristoyl pocket fixes the αI helix in one conformation that does not clash with the SH2 domain and reassembles the core even in the presence of type-II ATP-site inhibitors. (d) Mechanism proposed in P3 to explain imatinib-induced disassembly of Abl's core. Binding of imatinib to the ATP site does not disassemble the core. However, after saturating the ATP site, low-affinity binding of imatinib to the allosteric site exerts forces onto the KD–SH2 interface that lead to core disassembly. The disassembled state is not dynamic but a fixed conformation.


Under healthy conditions, Abl regulation is achieved by a set of interactions within its regulatory core consisting sequentially of the SH3 domain, SH2 domain, and kinase domain (KD), which is preceded by an  60–80-residue-long N-terminal tail (N-cap) that is myristoylated in the Abl 1b isoform (Nagar et al., 2003). Crystal structures of the autoinhibited Abl 1b core with the myristoylated N-cap (Nagar et al., 2003; Hantschel et al., 2003; Nagar et al., 2006) reveal a tight, almost spherical, assembly (Fig. 1a). We have shown previously by small-angle X-ray scattering (SAXS) and NMR chemical shifts (Skora et al., 2013; hereafter publication P1) that the apo form of the regulatory core (residues 83–534, Abl83–534, isoform 1b numbering used throughout) adopts the same assembled conformation as observed in the crystal structures of the autoinhibited Abl 1b core. The assembly of the core impedes efficient substrate binding (Nagar et al., 2003), presumably by hindering hinge motions between the KD C- and N-lobes (Sonti et al., 2018; hereafter publication P2), and reduces the kinase activity by 10 to 100 times relative to the isolated kinase domain (Hantschel, 2012; Sonti et al., 2018). In contrast, the active state of Abl is thought to require the disassembly of the core to make the substrate binding site accessible and expose the protein–protein contact sites of the SH2 and SH3 domains.

Surprisingly, we observed in P1 that binding of the ATP-site inhibitor imatinib disassembles the core into an arrangement where SH3 and SH2 domains move with high-amplitude nanosecond motions relative to the KD (Fig. 1b). The additional binding of the allosteric inhibitor GNF-5 to the myristoyl binding pocket then led to a reassembly of Abl's core (Fig. 1c). These conclusions were derived from multiple pieces of evidence (see below) and based on backbone resonance assignments obtained earlier on the KD alone (Vajpai et al., 2008a, b) as well as further triple-resonance backbone assignment experiments on the regulatory core in P1. The assignment experiments showed that the ATP-site inhibitors imatinib, nilotinib, and dasatinib induce the strongest chemical shift changes at the ATP site (see, for example, P1, therein supplementary Fig. S5C, and Vajpai et al., 2008b, therein Fig. 3C), whereas GNF-5 induced the strongest chemical shift changes in the vicinity of the myristoyl pocket in agreement with the expected binding modes of all inhibitors.

Multiple evidences for the disassembly of the Abl core by inhibitor binding to the ATP site were obtained from 15N T1 and T2 relaxation data, residual dipolar coupling (RDC) data, and 1H–15N chemical shifts for 286 residues covering  80 % of the SH3 and SH2 domains and  60 % of the KD of the Abl83–534 construct. Furthermore, the imatinib-induced disassembly was observed in orthogonal SAXS experiments. This effect is counterintuitive, because the imatinib-bound form is inhibited and yet in a disassembled conformation that is normally associated with an active form of Abl. The disassembled conformation of the core was further corroborated in cellular experiments, which gave evidence that non-saturating, nanomolar concentrations of imatinib or nilotinib (a further ATP-site inhibitor) lead to phosphorylation of residue Y245, which resides in the linker between the SH2 and KD domains (Fig. 1a, b). The linker is only accessible in the disassembled state of the core but buried in the assembled state.

In publication P2 we extended these findings in a systematic way to 14 ATP-site ligands, comprising all FDA-approved Bcr-Abl inhibiting drugs. Compelling evidence by 1H–15N chemical shifts from  100 residues within the SH2-SH3 domain showed that all type-II ATP-site inhibitors, which induce an “inactive” (conserved Asp-Phe-Gly motif oriented outward from the catalytic site, “DFG out”) conformation of the activation loop (A-loop), disassemble the Abl regulatory core. In contrast, type-I ATP-site inhibitors, which lead to an “active” (“DFG-in” or “DFG-flipped”) conformation of the A-loop, leave the regulatory core in the assembled state. The type-II inhibitor-induced opening of the regulatory core was explained by a force from the inhibitor onto the A-loop and subsequently P-loop, which leads to a slight rotation (observed in crystal structures) of the kinase N-lobe towards the SH3 domain. This force as well as an additional force exerted by the flexible αI helix onto the SH2–KD interface breaks the delicate balance, which holds the assembled core together (Fig. 1c). Allosteric inhibitors bend the αI helix into a fixed conformation, which does not clash with the SH2–KD interface, and thereby keep the core assembled. Importantly, the type-II inhibitor-induced disassembly was observed in an identical manner for all investigated type-II inhibitors, i.e., imatinib, nilotinib, ponatinib, rebastinib, and bafetinib.

In a recent publication (Xie et al., 2022; hereafter P3), Kalodimos and coworkers described a crystal structure of a truncated Abelson kinase domain (KD, residues 248–518, Abl248–518) in complex with dasatinib in the ATP binding pocket and imatinib in the myristoyl binding pocket. The truncated KD had half of the C-terminal αI helix deleted, which covers part of the myristoyl binding pocket (Fig. 1a). These authors also provided ITC, NMR, and kinase activity data, which are related to the binding of imatinib to the allosteric site. Intriguingly, this allosteric binding appears to promote a disassembled state of the Abl regulatory core and higher kinase activity in mutants with reduced imatinib affinity for the ATP site. An increased kinase activity due to core disassembly is expected, since the assembled core has significantly lower kinase activity than the KD alone or an SH2-KD construct (Sonti et al., 2018). The authors observed an imatinib affinity of 10 µM for the allosteric pocket by ITC, which is 3 orders of magnitude lower than the affinity for the ATP site (Agafonov et al., 2014). Unfortunately, the ITC experiments were not carried out on a full regulatory core construct, where the presence of the adjacent SH2 and SH3 domains in the assembled state is expected to influence the conformation and binding properties of the allosteric pocket. Likewise, most NMR data were obtained only on the Abl KD but not on the full regulatory core. Nevertheless, the findings could be significant, as imatinib binding to the allosteric pocket and the concomitant increase in activity may be a relevant mechanism in patients with imatinib-resistant mutations at the ATP site.

The authors of P3 argue that the imatinib-induced opening of the Abl regulatory core (residues 83–534, Abl83–534), which was previously observed in P1 and P2, may indeed be caused by the binding to the allosteric site (Fig. 1d) and not as we had suggested by binding to the ATP site. This might have been possible in our reported NMR experiments, since the NMR concentrations are in the hundred-micromolar range. We regret that the authors of P3 have ignored the previous evidence that the ATP-site binding of imatinib opens the regulatory core. We show here by a simple titration that imatinib opens the regulatory core by binding to the ATP pocket with nanomolar affinity. A proper understanding of these mechanisms by taking into account all observations is crucial to make progress in this important area of rational drug development.

2 Experimental procedures

2.1 Protein expression and purification

The Abl regulatory core fragment Abl83–534 was expressed in non-deuterated, 15N-labeled form in Escherichia coli strain BL21(DE3) and purified as described previously in P2.

2.2 NMR spectroscopy and data analysis

Similar to our previous studies, the isotope-labeled Abl83–534 was concentrated to 79 µM (based on absorbance measurements, see below) and 300 µL volume in 10 mM TrisHCl, 100 mM NaCl, 2 mM EDTA, 2 mM TCEP, 0.02 % NaN3, pH 8.0 (“NMR buffer”). Imatinib was purchased from Selleck Chemicals GmbH and used without further purification. An imatinib 50 mM stock solution in DMSO was prepared by weighing in the required amount of dry imatinib. This stock was then diluted with NMR buffer to 0.5 mM imatinib, from which it was added to Abl83–534 at molar ratios of 0, 1 : 10, 3 : 10, 5 : 10, 7 : 10, 1 : 1, and 3 : 1 (imatinib : Abl83–534). The concentrations of the imatinib stock solutions and of Abl83–534 in the NMR sample were confirmed by absorbance measurements at 255 nm for imatinib (ε255= 3.3338 × 104 M−1 cm−1; Haque et al., 2016) and at 280 nm for Abl83–534 (ε280= 9.5230 × 104 M−1cm−1 derived by ExPASy, Gasteiger et al., 2003, from UniProt entry P00519, isoform 1b, residues 83–534), respectively, using a Nanodrop 2000 spectrometer (Thermo Scientific). Due to further errors from light scattering and pipetting, the indicated imatinib and Abl83–534 concentrations are presumably correct within 10 %–20 %. The good agreement with the theoretical binding curve (see below) corroborates this estimate.

All NMR experiments were performed at 303 K on a Bruker Ascend 600 MHz spectrometer equipped with a TCI triple-resonance cryoprobe. 1H–15N TROSY (transverse relaxation optimized spectroscopy) experiments were recorded with 140 (15N) × 1024 (1H) complex points and acquisition times of 42 ms (15N) and 48 ms (1H). Data were processed with the NMRPipe software package (Delaglio et al., 1995) and analyzed with SPARKY (Goddard and Kneller, 2008). For quantitative analysis, resonances of the entire titration data set were fitted with the program nlinLS contained in NMRPipe.

Figure 2Correlation between imatinib binding to the Abl ATP site and imatinib-induced Abl core disassembly observed by NMR. (a) Individual 1H–15N TROSY resonances of selected residues of the Abl83–534 core, which show characteristic shifts for the apo and imatinib-bound state, as a function of imatinib concentration ([Abl83–534] = 79 µM). Molar ratios of imatinib vs. Abl83–534 are given above the panels. (b) Occupancies of Abl83–534 states as a function of imatinib concentration derived from resonance intensities in (a). Predicted imatinib occupancies of orthosteric (red) and allosteric pockets (blue) according to the equilibrium model (d) are shown as dashed lines for parameters [Abl83–534] = 79 µM, KDO= 10 nM, and KDA= 10 µM. (c) Crystal structure of Abl regulatory core (PDB ID: 2FO0) in complex with ATP-site inhibitor PD166326 (magenta sticks) showing the locations of residues V130, G149, N316, and D382 (cyan spheres) whose resonances are analyzed in panels (a) and (b). (d) Chemical equilibrium model describing the binding of the imatinib ligand (L) to Abl's allosteric (dissociation constant KDA) and orthosteric (dissociation constant KDO) binding sites. E0–E3 present Abl apo and various imatinib-bound states.


Theoretical Abl imatinib binding curves were calculated by solving the respective mass action law equations for a four-state model (see also Fig. 2d) using Mathematica (Wolfram Research, Inc.). These equations are the following:


where E0, E1, E2, E3, L, Et, and Lt present the concentrations of apo Abl, Abl with imatinib bound to ATP site, Abl with imatinib bound to allosteric site, Abl with imatinib bound to both sites, free imatinib, total Abl, and total imatinib, respectively. KDO, KDA are the dissociation constants for binding to the ATP site (orthosteric site) and allosteric site, respectively.

3 Results and discussion

3.1 Detailed discussion of previous evidence on ATP-site inhibitor-induced opening of Abl's regulatory core

Kalodimos and colleagues argue that we had not stated the imatinib concentrations in our work. While this is true for publication P1, where we had only stated that Abl83–534 had formed a complex with imatinib at concentrations of 150–200 µM for the NMR experiments, publication P2 clearly indicated a 3 : 1 ligand : protein ratio for SH3-SH2-KD Abl83–534 concentrations of  100 µM. These concentrations are in the range where effects of allosteric imatinib binding at a KD of 10 µM would become appreciable and the regulatory core could open due to imatinib binding to the allosteric site. However, for the reasons given in the next paragraphs, this argumentation is not correct.

P1 clearly showed that not only imatinib but also nilotinib disassembles the regulatory core. The evidence was given by 1H–15N chemical shifts within the SH2-SH3 domains as well as by SAXS data, which are identical for the nilotinib- and imatinib-bound SH3-SH2-KD Abl83–534 construct. However, no binding of nilotinib to the allosteric pocket was observed in P3. The cellular experiments on Bcr-Abl, reported in P1, show that 10–100 nM concentrations of either imatinib or nilotinib lead to phosphorylation of residue Y245, whereas higher inhibitor concentrations prevent phosphorylation. This observation can only be explained by an opening of the regulatory core by high-affinity imatinib or nilotinib binding to the ATP site, such that at non-saturating inhibitor concentrations a fraction of the Bcr-Abl molecules is inhibitor-bound with a disassembled core, whereas the remaining apo fraction is active and phosphorylates Y245 of the disassembled, inhibitor-bound fraction. This contradicts an opening of the regulatory core via low-affinity binding to the allosteric pocket postulated in P3.

In publication P2 we observed the inhibitor-induced disassembly in an identical manner for all investigated type-II inhibitors, i.e., imatinib, nilotinib, ponatinib, rebastinib, and bafetinib. Of these, imatinib, nilotinib, and ponatinib were tested in P3 for allosteric pocket binding, with imatinib having micromolar affinity, ponatinib much weaker affinity than imatinib, and nilotinib no observable binding. The observed core disassembly by all investigated type-II inhibitors in P1 and P2 contradicts the hypothesis of P3 that the disassembly is caused by binding to the allosteric pocket.

It is doubtful whether the imatinib KD value of 10 µM for the allosteric pocket determined on the KD construct in P3 is relevant in the context of the entire Abl regulatory core. Indeed well before the publication of P3 Skora and Jahnke (2017) had already assayed both ATP- and allosteric-site binding of imatinib to Abl83–534 by 19F-labeled competitive binders to the ATP and allosteric sites. No displacement of the 19F-labeled reporter for the allosteric site (KD= 43 µM) was detectable for an Abl83–534 concentration of 4 µM and concentrations of reporter ligand and imatinib of 25 µM each. This indicates that the imatinib affinity to the allosteric site of Abl's regulatory core must be in the high double-digit micromolar range or even weaker, which disagrees with the value of 10 µM reported in P3. Very likely, the additional coordination by the SH2 and SH3 domains and a subsequent rearrangement of the αI helix reduce the affinity in the context of the entire Abl regulatory core. Albeit highly relevant, the work by Skora and Jahnke (2017) is not cited in P3.

In P3, Kalodimos and colleagues argue that our explanation of an imatinib-induced push via the closed A-loop towards the SH3 domain, leading to core disassembly, is not valid, since they observed a closed A-loop in the assembled state in recent work on an apo SH3-SH2-KD fragment, which they compared to obtained solution NMR structures of the KD alone (Xie et al., 2020). However, the apo conformation of the A-loop in SH3-SH2-KD is irrelevant when imatinib fills the ATP pocket and exerts additional forces. Moreover, the A-loop in the apo form is certainly not in a single conformation but in dynamical exchange. We have reported a dynamical equilibrium of the A-loop already in Vajpai et al. (2008b) even in the presence of inhibitors as well as in P1 (their Fig. S2) where many resonances of the A-loop were broadened beyond detection due to conformational exchange for both the apo form and the GNF-5 complex. In contrast, binding of imatinib rigidifies the A-loop to the “closed” conformation of the crystal structure (Vajpai et al., 2008b). It also needs to be indicated that the solution structures of the Abl248–534 KD construct (Xie et al., 2020), on which the argument is based, are of low definition since they were derived from only 867/849/729 NOE – nuclear Overhauser enhancement (Xie et al., 2020, their Supplementary Table S1 for the structures named active/I1/I2, respectively) – and 461/458/496 dihedral (structures active/I1/I2, ibidem; the origin of the dihedral constraints is not documented) constraints. This corresponds to at most 3 NOE and 2 dihedral constraints per residue for these structures. Hence, a well-defined A-loop conformation cannot be postulated without additional evidence.

3.2 Imatinib titration to Abl's regulatory core followed by TROSY

To further characterize the binding of imatinib to Abl, we have carried out a titration of imatinib to the Abl regulatory core construct (SH3-SH2-KD, Abl83–534, 79 µM) used in our previous studies and followed the response of 1H–15N resonances in a TROSY experiment (Fig. 2). Well-separated resonances are observed (Fig. 2a), for example, for residues V130 and G149 in the SH3 and SH2 domains as well as for N316 and D382 in the KD close to the ATP site (Fig. 2c). The addition of imatinib from 0 to 240 µM leads to the appearance of a second set of resonances for these residues, which become dominant at high concentrations. Many further residues such as V92, Y283, G340, A384, F444, G455, and F505 show an identical imatinib-dependent effect (see full spectra in Fig. S1 in the Supplement). As shown before in P1 and P2, the appearance of the second set of resonances upon imatinib binding extends throughout the entire SH3-SH2 and kinase domains. This phenomenon corresponds to a slow exchange between the assembled apo Abl core and the disassembled imatinib-bound Abl core. Based on the chemical shift separations, the exchange rate must be slower than 2π× 0.6 ppm × 60 MHz  200 s−1. This is in agreement with a considerable ( 103) slowing of the apparent on- (14 s−1 at 250 µM imatinib) and off-rates (0.005 s−1) observed in vitro for imatinib binding to the kinase domain, which is caused by a conformational change after binding (Agafonov et al., 2014). Very likely, the respective exchange rates for the full regulatory core are even slower.

Notably the ratio of the resonance intensities of the apo (Ia) and imatinib-bound (Ii) forms of the individual residues in the SH3 and SH2 domains and close to the ATP site changes identically with imatinib concentration. This is evident from a plot of the intensity ratios Ii/(Ii+Ia), which equals the relative population pi of the imatinib-bound form versus the added imatinib concentration (Fig. 2b). For the SH3/SH2 residues V130 and G149 (indicative of Abl core disassembly) as well as for the ATP-site residues N316 and D382 (indicative of ATP-site binding), the dependence of pi on the imatinib concentration is identical, and its increase is almost quantitative with added imatinib up to the concentration of Abl SH3-SH2-KD. For comparison, Fig. 2b also depicts the theoretical binding curves of a two-site binding model with KDO (orthosteric ATP site) = 10 nM and KDA (allosteric site) = 10 µM. Clearly, both the SH3/SH2 and the ATP-site residues exhibit a dependence on the imatinib concentration that is expected for the high-affinity orthosteric ATP-site binding (red dashed lines) and not for the low-affinity allosteric-site binding (blue dashed lines). These data in combination with the evidence presented in P1 and P2 unequivocally show that imatinib binds with the expected nanomolar affinity to the ATP site and at the same time disassembles Abl's regulatory core, whereas binding to the allosteric site is irrelevant for the observed core disassembly.

3.3 Additional problematic points in P3

Publication P3 contains a number of further problematic points that weaken the evidence of the described experiments and make their results hard to reproduce. We are surprised that these problems escaped the refereeing and editorial process. A request to the Journal of Molecular Biology (JMB) to address this criticism in an editorial correspondence between us and the authors of P3 remained unheeded.

  1. With the exception of the sequence used for the crystal structure, it is often not specified which Abl constructs were used for the measurements. For example, there is no indication of the amino acid sequence of the Abl KD, AblFK, AblG269E/T334I, AblV272H/A363V, and Abl constructs used for the NMR, ITC, and kinase assay experiments. Thus, it remains unclear whether the entire αI helix was present or whether the truncated crystal structure construct had been used.

  2. In particular, it would have been very important to compare directly a construct harboring the entire αI helix with the truncated crystal structure construct. Both NMR and ITC experiments should also have been carried out on full regulatory core constructs and not only on Abl KD, in order to understand the effects of the adjacent SH2 and SH3 domains on the imatinib binding.

  3. The conclusions of P3 heavily depend on the ITC data. However, syringe concentrations of imatinib, other ATP-site blocking inhibitors, myristic peptide, GNF-5, and the Abl constructs themselves are not properly indicated for the crucial ITC titrations shown in their Figs. 1, S1, S2, S3, S5, and S8. Thus, it is impossible for others to reproduce these data.

  4. Their Fig. 4B shows a small region of a methyl spectrum of the Abl regulatory core construct (termed AblFK by the authors) in complex with imatinib in comparison to other Abl complexes. The imatinib concentration is not indicated. It would have been crucial for the conclusions of P3 to vary the imatinib concentration in this experiment. Furthermore, the origin of the black peak in their Fig. 4B, labeled “Abl” is completely unclear as the sequence of the “Abl” is not indicated (see above). As the conclusions from their Fig. 4B are very important for the entire P3 publication, full spectra of all constructs should also have been shown in its Supplementary Information.

  5. Their Fig. 5 shows a titration of imatinib added to Abl KD constructs monitored by methyl resonances. Again, neither imatinib nor Abl concentrations are indicated. Intriguingly, the left spectrum for V357 (panel A, row 2), which is presumably the apo form according to the concentration arrow at the top of the figure, does not agree with the blue spectrum on the right, which is annotated as apo Abl by the color legend at the top. Furthermore, the color code for the orange spectra shown in Fig. 5B, C is not explained. Full spectra for these titrations should also have been shown in the Supplementary Information.

  6. The authors of P3 argue that they developed a new method to differentiate Abl allosteric inhibitors from activators by monitoring resonances of αI-helix residues. However, a highly similar method (using 1H–15N instead of 1H–13C observations) had already been described and used successfully by the Novartis group many years ago (Jahnke et al., 2010). This work is not properly acknowledged.

  7. In addition, P3 contains many typos and other inconsistencies, which make the findings extremely hard to follow. Such problems are, for example, a wrong labeling of amide 1HN resonances as 13C in their Fig. 3B, a wrong labeling of the statistical significances in Fig. 6, a definition of kex as kon[imatinib] +koff, and a “lorem ipsum” statement in their Fig. 6A (the latter has now been removed by JMB without indicating the erratum as the so far (8 May 2022) only reaction to the present note).

4 Conclusion

In summary, previous data and the new evidence presented here unequivocally show that binding of imatinib to Abl's myristoyl pocket does not cause the observed disassembly of its regulatory core. Rather, the disassembly must be caused by imatinib binding to the ATP site and forces transmitted from there to the interface between the KD and the SH3-SH2 domains as explained in P2. Careful documentation of experimental procedures and taking into account all observations pertinent to a system as complicated as Abl is the only way forward to an in-depth understanding of its function and towards the goal of rational intervention.

Data availability

NMR raw and processed data in NMRPipe format have been deposited in the Zenodo repository under (Grzesiek et al., 2022).


The supplement related to this article is available online at:

Author contributions

JP and SG conceived the study. JP recorded the NMR experiments. JP, JH, and SG analyzed the data. SG, JP, and RS wrote the article.

Competing interests

The contact author has declared that neither they nor their co-authors have any competing interests.


Publisher’s note: Copernicus Publications remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Lukasz Skora and Wolfgang Jahnke​​​​​​​ are gratefully acknowledged for helpful discussions.

Financial support

This research has been supported by the Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (grant nos. 31-149927, 31-173089, and 31-201270) and the Krebsliga Schweiz (grant no. KFS-3603-02-2015).

Review statement

This paper was edited by Geoffrey Bodenhausen and reviewed by Paul Schanda and two anonymous referees.


Agafonov, R. V., Wilson, C., Otten, R., Buosi, V., and Kern, D.: Energetic dissection of Gleevec's selectivity toward human tyrosine kinases, Nat. Struct. Mol. Biol., 21, 848–853,, 2014. 

Braun, T. P., Eide, C. A., and Druker, B. J.: Response and Resistance to BCR-ABL1-Targeted Therapies, Cancer Cell, 37, 530–542,, 2020.​​​​​​​ 

Deininger, M. W., Goldman, J. M., and Melo, J. V.: The molecular biology of chronic myeloid leukemia, Blood, 96, 3343–3356, 2000. 

Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A.: NMRPipe: a multidimensional spectral processing system based on UNIX pipes, J. Biomol. NMR, 6, 277–293,, 1995. 

Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R. D., and Bairoch, A.: ExPASy: The proteomics server for in-depth protein knowledge and analysis, Nucleic Acids Res., 31, 3784–3788,, 2003. 

Goddard, T. D. and Kneller, D. G.: SPARKY, version 3, University of California, (last access: 18 May 2022), 2008. 

Grzesiek, S., Paladini, J., Habazettl, J., and Sonti, R.: Imatinib disassembles the regulatory core of Abelson kinase by binding to its ATP site and not by binding to its myristoyl pocket, Zenodo [data set],, 2022. 

Hantschel, O.: Structure, regulation, signaling, and targeting of abl kinases in cancer, Genes Cancer, 3, 436–46,, 2012. 

Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., and Superti-Furga, G.: A myristoyl/phosphotyrosine switch regulates c-Abl, Cell, 112, 845–857,, 2003. 

Hantschel, O., Grebien, F., and Superti-Furga, G.: The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL, Cancer Res., 72, 4890–4895,, 2012. 

Haque, M. A., Bakhshi, V., Surekha, D., Gouthami, B., Reddy, C. H. P., and Yakamma, B.: Development of UV-Spectrophotometric method for the determination of imatinib mesylate (ITM) in bulk and formulation, International Journal of Pharma Research and Health Sciences, 4, 1130–1135, 2016. 

Jahnke, W., Grotzfeld, R. M., Pellé, X., Strauss, A., Fendrich, G., Cowan-Jacob, S. W., Cotesta, S., Fabbro, D., Furet, P., Mestan, J., and Marzinzik, A. L.: Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay, J. Am. Chem. Soc., 132, 7043–7048,, 2010. 

Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., and Kuriyan, J.: Structural basis for the autoinhibition of c-Abl tyrosine kinase, Cell, 112, 859–871,, 2003. 

Nagar, B., Hantschel, O., Seeliger, M., Davies, J. M., Weis, W. I., Superti-Furga, G., and Kuriyan, J.: Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase, Mol. Cell, 21, 787–798,, 2006. 

O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., Metcalf, C. A., Tyner, J. W., Loriaux, M. M., Corbin, A. S., Wardwell, S., Ning, Y., Keats, J. A., Wang, Y., Sundaramoorthi, R., Thomas, M., Zhou, D., Snodgrass, J., Commodore, L., Sawyer, T. K., Dalgarno, D. C., Deininger, M. W. N., Druker, B. J., and Clackson, T.: AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance, Cancer Cell, 16, 401–412,, 2009. 

Pendergast, A. M.: The Abl family kinases: mechanisms of regulation and signaling, Adv. Cancer Res., 85, 51–100,, 2002. 

Réa, D., Mauro, M. J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., Turkina, A., Kim, D.-W., Apperley, J. F., Abdo, A., Fogliatto, L. M., Kim, D. D. H., le Coutre, P., Saussele, S., Annunziata, M., Hughes, T. P., Chaudhri, N., Sasaki, K., Chee, L., García-Gutiérrez, V., Cortes, J. E., Aimone, P., Allepuz, A., Quenet, S., Bédoucha, V., and Hochhaus, A.: A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs, Blood, 138, 2031–2041,, 2021. 

Rowley, J. D.: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, Nature, 243, 290–293,, 1973. 

Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., and Sawyers, C. L.: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency, J. Clin. Invest., 117, 2562–2569,, 2007. 

Skora, L. and Jahnke, W.: 19F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors, ACS Med. Chem. Lett., 8, 632–635,, 2017. 

Skora, L., Mestan, J., Fabbro, D., Jahnke, W., and Grzesiek, S.: NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors, P. Natl. Acad. Sci. USA, 110, E4437–E4445,, 2013. 

Sonti, R., Hertel-Hering, I., Lamontanara, A. J., Hantschel, O., and Grzesiek, S.: ATP Site Ligands Determine the Assembly State of the Abelson Kinase Regulatory Core via the Activation Loop Conformation, J. Am. Chem. Soc., 140, 1863–1869,, 2018. 

Vajpai, N., Strauss, A., Fendrich, G., Cowan-Jacob, S. W., Manley, P. W., Jahnke, W., and Grzesiek, S.: Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib, Biomol. NMR Assign., 2, 41–42,, 2008a. 

Vajpai, N., Strauss, A., Fendrich, G., Cowan-Jacob, S. W., Manley, P. W., Grzesiek, S., and Jahnke, W.: Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib, J. Biol. Chem., 283, 18292–18302,, 2008b. 

Van Etten, R. A.: Cycling, stressed-out and nervous: cellular functions of c-Abl, Trends Cell Biol., 9, 179–186,, 1999. 

Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., Buonamici, S., Hassan, A. Q., Lombardo, F., Iyer, V., Palmer, M., Berellini, G., Dodd, S., Thohan, S., Bitter, H., Branford, S., Ross, D. M., Hughes, T. P., Petruzzelli, L., Vanasse, K. G., Warmuth, M., Hofmann, F., Keen, N. J., and Sellers, W. R.: The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1, Nature, 543, 733–737,, 2017.  

Xie, T., Saleh, T., Rossi, P., and Kalodimos, C. G.: Conformational states dynamically populated by a kinase determine its function, Science, 370, eabc2754,, 2020. 

Xie, T., Saleh, T., Rossi, P., Miller, D., and Kalodimos, C. G.: Imatinib can act as an Allosteric Activator of Abl Kinase, J. Mol. Biol., 434, 167349,, 2022. 


US Food and Drug Administration.

Short summary
We show here that binding of the anticancer drug imatinib to the ATP site of Abelson kinase and not binding to its allosteric site coincides with the opening of the kinase regulatory core at nanomolar concentrations. This has implications for the understanding of Abelson’s kinase regulation and activity during medication as well as for the design of new Abelson kinase inhibitors.